NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Peking Union-Lawke Biomedical Development Limited back to previous page show list

Peking Union-Lawke Biomedical Development Limited

»
address: Address´╝Ü D101 Zhongguancun Life
Science Park, 29
Changping Shengmingyuan
Road, Beijing 102206
contact: Phone´╝Ü86-010-80720625
Fax´╝Ü86-010-80720652
E-mail´╝Üccld@lawke.com
key person: Chairman & CEO: Dr James Ho
Vice Chairman, Dr., and Vice President Dr.
VP Christine Dai
Prof. He Wei
Vice President Steven Dai

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: NO
partner in China: collaborates with Chinese Academy of Medical Sciences

SFDA approved: NO

Approvals:
GLP: YES
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
R&D: YES
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: NO

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: YES
New materials Safety Assessment: YES
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: YES
 

 Peking Union Lawke Biomedical Development Limited (PUL) is a joint-venture enterprise that was set up by Lawke Health International Limited and CAMS & PUMC. PUL integrates the functions of medical care, education, research and entrepreneurship. Lawke Health International Limited bridges the United States and China, with a goal to commercialize biotechnologies in the health-related fields. PUL is co-located with CCLD, and the CEO of PUL serves also as the Director of CCLD. PUL will facilitate the mission of Lawke Health International Limited in China to realize a synergy of technologies, products and services with utterly new concepts. PUL aims to set up a franchised clinical testing lab, to introduce and assimilate advanced laboratory testing technologies, and to develop new laboratory testing products to facilitate clinical diagnosis and treatment. Through consulting and training programs, PUL will strive to promote advanced clinical laboratory quality systems and managerial skills in order to further the development of clinical laboratories in Chinese hospitals. Taking clinical laboratory testing as its core service, PUL will endeavor to initiate new services in the field of medical care and public health, thus contributing to the continual improvement of people’s health

Suggested by CCLD's Academic Committee, the research and development goals and range tentatively include:

1. The application of LC/MS and ICP/MS in clinical laboratory testing: a) Doping tests for 2008 Olympic Game in Beijing, b) Research in laboratory testing methods and treatment plans concerning organic acid, amino acid, and fatty acid in genetic metabolic disorders, c) Element analysis, d) Projects and exploitation in clinical therapeutic drug monitoring. 2. The application and exploitation of gene and protein chips used in clinical laboratory test. 3. The application of pathological and molecular pathological technologies in disease diagnosis and classification. 4. Reference test method establishment and reference material verification. 5. Cancer marker test and anti-cancer gene drug monitoring. 6. Health quality assessment and the preventive measures as well as anti-aging research. 7. Growth and development examination of children and adolescents. 8. Research in clinical emergency tests for public health. 9. The development of community medical treatment system supported by clinical laboratory testing. 10. Projects of national urgent needs and governmental support.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.